MedTrace Logo

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

NCT01950741 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-04-29

Study results available
· View outcomes & findings →

Summary

Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.

Conditions

  • Exudative Age-related Macular Degeneration
  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

aflibercept

Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Jae Pil Shin, MD, PhD · Kyungbuk National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-05-31
Completion
2015-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01950741 on ClinicalTrials.gov